5 Jun 2017 15:45
Results of Annual General Meeting
LONDON, 5 June, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, announces that its Annual General Meeting (the "Meeting") was held on Monday 5 June 2017 at 2pm (London time). At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 26 April 2017 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 14 and 19 were passed as ordinary resolutions. Resolutions 15 to 18 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's website www.arixbioscience.com.
No | RESOLUTION | VOTESFOR | % | VOTESAGAINST | % | TOTAL VOTES | % of ISC VOTED | VOTESWITHHELD |
1 | To receive the Directors' report and the accounts for the Company for the period ended 31 December 2016 | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
2 | To approved the Directors' Remuneration Policy | 41,408,348 | 88.59 | 5,333,387 | 11.41 | 46,741,735 | 48.64% | 942 |
3 | To re-elect Dr Joseph Anderson as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
4 | To re-elect Sir John Banham as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
5. | To re-elect Professor Sir Chris Evans as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
6 | To re-elect Dr Franz Humer as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
7 | To re-elect Lord John Hutton of Furness as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
8 | To re-elect Professor Trevor Jones as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
9 | To re-elect Jonathan Peacock as a Director | 46,251,849 | 98.95 | 490,200 | 1.05 | 46,742,049 | 48.64% | 628 |
10. | To Re-elect James Rawlingson as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
11. | To re-elect David U'Prichard as a Director | 46,742,049 | 100.00 | 0 | 0.00 | 46,742,049 | 48.64% | 628 |
12 | To re-appoint PwC LLP as auditors of the Company | 46,741,735 | 100.00 | 0 | 0.00 | 46,741,735 | 48.64% | 942 |
13 | To authorise the Audit & Risk Committee of the Company to fix the remuneration of the auditors | 46,741,735 | 100.00 | 0 | 0.00 | 46,741,735 | 48.64% | 942 |
14 | To authorise the Directors to allot shares | 46,742,049 | 100.00 | 628 | 0.00 | 46,742,677 | 48.64% | 0 |
15 | To authorise the Directors to disapply statutory pre-emption rights in respect of 5% of the Company's issued share capital | 44,140,479 | 94.43 | 2,601,570 | 5.57 | 46,742,049 | 48.64% | 628 |
16 | To authorise the Directors to disapply statutory pre-emption rights in respect of an additional 5% of the Company's issued share capital | 43,277,458 | 92.59 | 3,464,591 | 7.41 | 46,742,049 | 48.64% | 628 |
17 | To authorise the Company to buy back shares | 46,740,165 | 99.99 | 2,512 | 0.01 | 46,742,677 | 48.64% | 0 |
18 | To authorise the Directors to call a general meeting other than an annual general meeting on not less than 14 clear days' notice | 46,742,677 | 100.00 | 0 | 0.00 | 46,742,677 | 48.64% | 0 |
19 | To authorise the Company to purchase its own Deferred Shares | 46,741,735 | 100.00 | 942 | 0.00 | 46,742,677 | 48.64% | 0 |
Notes:
1. Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.
2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
3. The number of shares in issue at 6:00 p.m. on 1 June 2017 was 96,091,083 (the "Share Capital"). The Company does not hold any shares in treasury.
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism which can be accessed at www.hemscott.com/nsm.do
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com